Prostaglandin-endoperoxide Synthase 1: A Potential Drug Target Or Biomarker

Target Name: PTGS1

NCBI ID: G5742

PTGS1

Prostaglandin-endoperoxide Synthase 1: A Potential Drug Target Or Biomarker

Prostaglandin-endoperoxide synthase 1 (PTGS1) is a gene that encodes a protein involved in the production of prostaglandins, which are a family of hormone-like compounds that play important roles in various physiological processes in the body. PTGS1 is a transcript variant of the gene that has been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, PTGS1 has become a focus of interest for researchers and pharmaceutical companies as a potential drug target or biomarker.

The prostaglandin system is a complex biochemical pathway that involves the production of a variety of hormones and signaling molecules that play important roles in various physiological processes, including pain perception, inflammation, and blood vessel regulation. Prostaglandins are generated from the synthesis of arachidonic acid, which is a fatty acid that is derived from the breakdown of certain foods such as meat and eggs. When arachidonic acid is broken down, it is converted into prostaglandins, which are characterized by their ability to bind to specific receptors on the surface of cells and trigger a variety of physiological responses.

PTGS1 is a key enzyme involved in the production of prostaglandins. It is a transcript variant of the gene that encodes the protein, and it has been shown to be involved in the production of a variety of prostaglandins, including prostaglandin E2 (PGE2), prostaglandin E4 (PGE4), and prostaglandin F2 (PGF2). These prostaglandins play important roles in various physiological processes, including pain perception, inflammation, and blood vessel regulation.

One of the key functions of PTGS1 is its role in the production of prostaglandin E2 (PGE2). PGE2 is a potent hormone that is involved in the development and progression of cancer, and it has been shown to play a key role in the development of various types of cancer, including breast, ovarian, and prostate cancer. In addition, PGE2 has also been shown to contribute to the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases.

PTGS1 has also been shown to be involved in the production of prostaglandin F2 (PGF2). PGF2 is another prostaglandin that is involved in the development and progression of cancer, and it has been shown to play a key role in the development of various types of cancer, including colon cancer. In addition, PGF2 has also been shown to contribute to the development of autoimmune disorders, such as rheumatoid arthritis and lupus.

The potential implications ofPTGS1 as a drug target or biomarker are significant. If successful, drugs that target PTGS1 could be used to treat a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In addition, the development of drugs that target PTGS1 could also provide valuable insights into the biology of this protein and its role in various physiological processes.

In conclusion, PTGS1 is a protein that is involved in the production of prostaglandins, which are a family of hormone-like compounds that play important roles in various physiological processes in the body. The development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders have been shown to be influenced by the activity of PTGS1, making it a focus of interest for researchers and pharmaceutical companies as a potential drug target or biomarker. Further research is needed to fully understand the role of PTGS1 in these diseases and to develop effective treatments.

Protein Name: Prostaglandin-endoperoxide Synthase 1

Functions: Dual cyclooxygenase and peroxidase that plays an important role in the biosynthesis pathway of prostanoids, a class of C20 oxylipins mainly derived from arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate, AA, C20:4(n-6)), with a particular role in the inflammatory response. The cyclooxygenase activity oxygenates AA to the hydroperoxy endoperoxide prostaglandin G2 (PGG2), and the peroxidase activity reduces PGG2 to the hydroxy endoperoxide prostaglandin H2 (PGH2), the precursor of all 2-series prostaglandins and thromboxanes. This complex transformation is initiated by abstraction of hydrogen at carbon 13 (with S-stereochemistry), followed by insertion of molecular O2 to form the endoperoxide bridge between carbon 9 and 11 that defines prostaglandins. The insertion of a second molecule of O2 (bis-oxygenase activity) yields a hydroperoxy group in PGG2 that is then reduced to PGH2 by two electrons (PubMed:7947975). Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the generation of thromboxane A2 (TXA2), which promotes platelet activation and aggregation, vasoconstriction and proliferation of vascular smooth muscle cells (Probable). Can also use linoleate (LA, (9Z,12Z)-octadecadienoate, C18:2(n-6)) as substrate and produce hydroxyoctadecadienoates (HODEs) in a regio- and stereospecific manner, being (9R)-HODE ((9R)-hydroxy-(10E,12Z)-octadecadienoate) and (13S)-HODE ((13S)-hydroxy-(9Z,11E)-octadecadienoate) its major products (By similarity)

The "PTGS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PTGS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets